

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

October 5, 2022

Kelly Deck Chief Financial Officer Inhibrx, Inc. 11025 N. Torrey Pines Rd. Suite 200 La Jolla, CA 92037

Re: Inhibrx, Inc.

Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 28, 2022 Form 10-Q for the Fiscal Quarter Ended June 30, 2022 Filed August 8, 2022 File No. 001-39452

Dear Kelly Deck:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences